Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT00668798
Other study ID # CMV/MM0105/FFM
Secondary ID
Status Suspended
Phase N/A
First received April 25, 2008
Last updated April 28, 2008
Start date January 2005
Est. completion date March 2008

Study information

Verified date April 2008
Source Johann Wolfgang Goethe University Hospitals
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Office for Consumer's Safety and Veterinarian Medicine
Study type Observational

Clinical Trial Summary

Cytomegalovirus infection threatens preterm infant. We investigated, whether thawed breast milk is a mode of transmission


Description:

Preterm infants are at risk of symptomatic human cytomegalovirus infections transmitted by breast milk. This study evaluates incidence, timing, and clinical rlevance of acquired human CMV infections in preterm infants younger than 32 weeks of gestational age receiving maternal thawed frozen breast milk until 33 completed weeks of gestational age.


Recruitment information / eligibility

Status Suspended
Enrollment 58
Est. completion date March 2008
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender Both
Age group 24 Weeks to 31 Weeks
Eligibility Inclusion Criteria:

- preterm infants of less than 32 weeks of gestation

Exclusion Criteria:

- preterm infant of 32 weeks of gestational age or older, feeding with solely formula milk

- ourborn infants

- retroviral infection

- CMV status of mother unclear

- informed consent missing

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Childrens Hospital Goethe University Frankfurt

Sponsors (1)

Lead Sponsor Collaborator
Johann Wolfgang Goethe University Hospitals

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet. 2001 Feb 17;357(9255):513-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary CMV status of preterm infants 2005-2008 No
Secondary clinical manifestations of CMV infection 2005-2008 No
See also
  Status Clinical Trial Phase
Completed NCT01195571 - Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age Phase 1
Recruiting NCT01248598 - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis N/A
Active, not recruiting NCT05575492 - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age Phase 1/Phase 2
Recruiting NCT03665675 - Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Early Phase 1
Completed NCT00456664 - CMV Disease and IRIS in HIV-1 Infected Persons N/A
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01160081 - Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis N/A
Completed NCT00467532 - Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients N/A
Terminated NCT03127787 - Clinical Performance Evaluation of DxN CMV Assay
Completed NCT00366717 - Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy N/A
Completed NCT00815802 - Detection of Human Cytomegalovirus in the Saliva N/A
Completed NCT01646645 - Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT00214240 - The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease N/A
Completed NCT00330018 - Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Phase 3
Completed NCT01895049 - Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria Phase 4
Completed NCT02083042 - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients N/A
Completed NCT01162330 - The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment N/A
Completed NCT01008540 - Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients N/A